{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:52Z","timestamp":1793774812526,"version":"4.6.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since serum tryptase levels are elevated in some patients with myeloproliferative disorders, we examined their utility in identifying a subset of patients with hypereosinophilic syndrome (HES) and an underlying myeloproliferative disorder. Elevated serum tryptase levels (&amp;gt; 11.5 ng\/mL) were present in 9 of 15 patients with HES and were associated with other markers of myeloproliferation, including elevated B12 levels and splenomegaly. Although bone marrow biopsies in these patients showed increased numbers of CD25+ mast cells and atypical spindle-shaped mast cells, patients with HES and elevated serum tryptase could be distinguished from patients with systemic mastocytosis and eosinophilia by their clinical manifestations, the absence of mast cell aggregates, the lack of a somatic KIT mutation, and the presence of the recently described fusion of the Fip1\u2013like 1 (FIP1L1) gene to the platelet-derived growth factor receptor \u03b1 gene (PDGFRA). Patients with HES and elevated serum tryptase were more likely to develop fibroproliferative end organ damage, and 3 of 9 died within 5 years of diagnosis in contrast to 0 of 6 patients with normal serum tryptase levels. All 6 patients with HES and elevated tryptase treated with imatinib demonstrated a clinical and hematologic response. In summary, elevated serum tryptase appears to be a sensitive marker of a myeloproliferative variant of HES that is characterized by tissue fibrosis, poor prognosis, and imatinib responsiveness.<\/jats:p>","DOI":"10.1182\/blood-2003-01-0006","type":"journal-article","created":{"date-parts":[[2003,4,8]],"date-time":"2003-04-08T02:17:00Z","timestamp":1049768220000},"page":"4660-4666","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":322,"title":["Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness"],"prefix":"10.1182","volume":"101","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Law","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gary","family":"Gilliland","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cools","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Nutman","sequence":"additional","affiliation":[{"name":"From the Laboratory of Parasitic Diseases and the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217321808400_REF1","doi-asserted-by":"crossref","unstructured":"Chusid MJ, David DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975;54: 1-27.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"2020021217321808400_REF2","doi-asserted-by":"crossref","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83: 2759-2779.","DOI":"10.1182\/blood.V83.10.2759.2759"},{"key":"2020021217321808400_REF3","doi-asserted-by":"crossref","unstructured":"Assa'ad AH, Spicer RL, Nelson DP, Zimmerman N, Rothenberg ME. Hypereosinophilic syndromes. Chem Immunol. 2000;76: 208-229.","DOI":"10.1159\/000058787"},{"key":"2020021217321808400_REF4","doi-asserted-by":"crossref","unstructured":"Chang H, Leong K, Koh D, Lee S. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93: 1651-1657.","DOI":"10.1182\/blood.V93.5.1651"},{"key":"2020021217321808400_REF5","doi-asserted-by":"crossref","unstructured":"Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341: 1112-1120.","DOI":"10.1056\/NEJM199910073411503"},{"key":"2020021217321808400_REF6","doi-asserted-by":"crossref","unstructured":"Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109: 540-548.","DOI":"10.1046\/j.1365-2141.2000.02097.x"},{"key":"2020021217321808400_REF7","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A novel tyrosine kinase created by the fusion of the PDG-FRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2020021217321808400_REF8","doi-asserted-by":"crossref","unstructured":"Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89: 167-172.","DOI":"10.7326\/0003-4819-89-2-167"},{"key":"2020021217321808400_REF9","unstructured":"McCarthy KP, Sloane JP, Kabarowski JH, Matutes E, Wiedemann LM. A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol. 1992;1: 173-179."},{"key":"2020021217321808400_REF10","doi-asserted-by":"crossref","unstructured":"Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100: 661-665.","DOI":"10.1182\/blood-2002-01-0203"},{"key":"2020021217321808400_REF11","doi-asserted-by":"crossref","unstructured":"Akin C, Kirshenbaum AS, Semere AS, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in myelomonocytic cells, T cells, and B cells from patients with mastocytosis. Exp Hematol. 2000;28: 140-147.","DOI":"10.1016\/S0301-472X(99)00145-9"},{"key":"2020021217321808400_REF12","doi-asserted-by":"crossref","unstructured":"Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91: 2731-2736.","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736"},{"key":"2020021217321808400_REF13","doi-asserted-by":"crossref","unstructured":"Gilbert HS, Krauss S, Pasternack B, Herbert V, Wasserman LR. Serum vitamin B12 content and unsaturated vitamin B12-binding capacity in myeloproliferative disease: value in differential diagnosis and as indicators of disease activity. Ann Intern Med. 1969;71: 719-729.","DOI":"10.7326\/0003-4819-71-4-719"},{"key":"2020021217321808400_REF14","doi-asserted-by":"crossref","unstructured":"Zittoun J, Farcet JP, Marquet J, Sultan C, Zittoum R. Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia. Blood. 1984;63: 779-783.","DOI":"10.1182\/blood.V63.4.779.779"},{"key":"2020021217321808400_REF15","doi-asserted-by":"crossref","unstructured":"Foster B, Schwartz LB, Devouassoux G, Metcalfe DD, Prussin C. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol. 2002;109: 287-293.","DOI":"10.1067\/mai.2002.121454"},{"key":"2020021217321808400_REF16","doi-asserted-by":"crossref","unstructured":"Sperr WR, Jordan J, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001;98: 2200-2209.","DOI":"10.1182\/blood.V98.7.2200"},{"key":"2020021217321808400_REF17","doi-asserted-by":"crossref","unstructured":"Valent P, Horny H, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25: 603-625.","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"2020021217321808400_REF18","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92: 10560-10564.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2020021217321808400_REF19","doi-asserted-by":"crossref","unstructured":"Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998;63: 1086-1094.","DOI":"10.1086\/302053"},{"key":"2020021217321808400_REF20","doi-asserted-by":"crossref","unstructured":"Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol. 1983;52: 321-324.","DOI":"10.1016\/0002-9149(83)90131-5"},{"key":"2020021217321808400_REF21","doi-asserted-by":"crossref","unstructured":"Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol. 1987;138: 2184-2189.","DOI":"10.4049\/jimmunol.138.7.2184"},{"key":"2020021217321808400_REF22","doi-asserted-by":"crossref","unstructured":"Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol. 1990;76: 186-193.","DOI":"10.1111\/j.1365-2141.1990.tb07870.x"},{"key":"2020021217321808400_REF23","doi-asserted-by":"crossref","unstructured":"Piliponsky AM, Gleich GJ, Bar I, Levi-Schaffer F. Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Molec Immunol. 2001;38: 1369-1372.","DOI":"10.1016\/S0161-5890(02)00090-1"},{"key":"2020021217321808400_REF24","doi-asserted-by":"crossref","unstructured":"Ochi HH, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med. 1999;190: 267-280.","DOI":"10.1084\/jem.190.2.267"},{"key":"2020021217321808400_","doi-asserted-by":"crossref","unstructured":"Woo C, Jeong DJ, Yoon S, et al. Eotaxin induces migration of RBL-2H3 mast cells via a Rac-ERK-dependent pathway. Biochem Biophys Res Comm. 2002;298: 392-397.","DOI":"10.1016\/S0006-291X(02)02432-4"},{"key":"2020021217321808400_REF26","doi-asserted-by":"crossref","unstructured":"De Paulis A, Annunziato F, Di Gioia L, et al. Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol. 2001; 124: 146-150.","DOI":"10.1159\/000053694"},{"key":"2020021217321808400_REF27","doi-asserted-by":"crossref","unstructured":"Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional cytokines. Immunol Today. 1990;11: 458-464.","DOI":"10.1016\/0167-5699(90)90176-A"},{"key":"2020021217321808400_REF28","doi-asserted-by":"crossref","unstructured":"Kobayashi H, Gleich GJ, Butterfield JH, Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimui. Blood. 2002;99: 2214-2220.","DOI":"10.1182\/blood.V99.6.2214"},{"key":"2020021217321808400_REF29","doi-asserted-by":"crossref","unstructured":"Patella V, de Crescenzo G, Marino I, et al. Eosinophil granule proteins activate human heart mast cells. J Immunol. 1996;157: 1219-1225.","DOI":"10.4049\/jimmunol.157.3.1219"},{"key":"2020021217321808400_REF30","doi-asserted-by":"crossref","unstructured":"Piliponsky AM, Leich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE dependent activation of human lung and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood. 2003;101: 1898-1904.","DOI":"10.1182\/blood-2002-05-1488"},{"key":"2020021217321808400_REF31","doi-asserted-by":"crossref","unstructured":"Pesci A, Majori M, Piccoli ML, et al. Mast cells in bronchiolitis obliterans organizing pneumonia: mast cell hyperplasia and evidence for extracellular release of tryptase. Chest. 1996;110: 383-391.","DOI":"10.1378\/chest.110.2.383"},{"key":"2020021217321808400_REF32","doi-asserted-by":"crossref","unstructured":"Matsunaga Y, Terada T. Mast cell populations in chronic inflammatory hepatobiliary diseases. Liver. 2000;20: 152-156.","DOI":"10.1034\/j.1600-0676.2000.020002152.x"},{"key":"2020021217321808400_REF33","doi-asserted-by":"crossref","unstructured":"Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol. 2001;12: 1668-1676","DOI":"10.1681\/ASN.V1281668"},{"key":"2020021217321808400_REF34","doi-asserted-by":"crossref","unstructured":"Apa DD, Cayan S, Polat A, Akbay E. Mast cells and fibrosis in testicular biopsies in male infertility. Arch Androl. 2002;48: 337-344.","DOI":"10.1080\/01485010290099183"},{"key":"2020021217321808400_REF35","doi-asserted-by":"crossref","unstructured":"Frungieri MB, Weidinger S, Meineke V, Ko\u0308hn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPAR\u03b3: possible relevance to human fibrotic disorders. Proc Natl Acad Sci U S A. 2002; 99: 15072-15077.","DOI":"10.1073\/pnas.232422999"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/4660\/1687714\/h81203004660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/4660\/1687714\/h81203004660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T17:05:38Z","timestamp":1704819938000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/12\/4660\/17022\/Elevated-serum-tryptase-levels-identify-a-subset"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,15]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-01-0006","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,15]]}}}